Valuation: Atossa Therapeutics, Inc.

Market Cap 16.19M 14.19M 13.08M 12.25M 22.97M 1.53B 23.45M 157M 60.85M 755M 60.79M 59.46M 2.62B P/E 2026 *
-0.43x
P/E 2027 * -0.54x
Enterprise Value 16.19M 14.19M 13.08M 12.25M 22.97M 1.53B 23.45M 157M 60.85M 755M 60.79M 59.46M 2.62B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+6.21%
1 week-6.47%
Current month-64.05%
1 month-62.02%
3 months-60.08%
6 months-80.98%
Current year-78.76%
1 week 1.7
Extreme 1.7
2.03
1 month 1.7
Extreme 1.7
5.3
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
127.5
10 years 1.7
Extreme 1.7
891
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 04/12/2023
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
12/05Free

Director

10,000 0.1161%
12/05
Ensisheim Partners LLC
OtherCompany 0 0%
12/05Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+6.21%-6.47%-85.72%-85.76% 16.19M
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +1.36%+7.58%+58.20%+97.05% 23.01B
Weighted average by Cap. +0.75%+8.71%+86.67%+140.73%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.79M -30.22M -28.29M -53.05M -3.53B -54.16M -363M -141M -1.74B -140M -137M -6.05B -39.31M -34.47M -31.77M -29.75M -55.78M -3.71B -56.94M -382M -148M -1.83B -148M -144M -6.36B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26/06/26 USD 1.880 +6.21% 377,885
25/06/26 USD 1.770 +1.14% 143,643
24/06/26 USD 1.750 -7.89% 304,043
23/06/26 USD 1.900 +3.83% 535,003
22/06/26 USD 1.830 -8.96% 469,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.880USD
Average target price
22.00USD
Spread / Average Target
+1,070.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock